Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/495
Title: | Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome | Authors: | Raposeiras-Roubín S. Caneiro Queija B. D'Ascenzo F. Kinnaird T. Ariza-Solé A. Manzano-Fernández S. Templin C. Lazar Velicki Xanthopoulou I. Cerrato E. Quadri G. Rognoni A. Boccuzzi G. Montabone A. Taha S. Durante A. Gili S. Magnani G. Autelli M. Grosso A. Flores Blanco P. Garay A. Varbella F. Tomassini F. Cobas Paz R. Cespón Fernández M. Muñoz Pousa I. Gallo D. Morbiducci U. Domínguez-Rodríguez A. Baz-Alonso J. Calvo-Iglesias F. Valdés M. Cequier Á. Gaita F. Alexopoulos D. Íñiguez-Romo A. Abu-Assi E. |
Keywords: | Bleeding;Reinfarction;Ticagrelor;Prasugrel;PARIS score;Acute coronary syndrome | Issue Date: | 1-Mar-2019 | Journal: | Revista Espanola de Cardiologia | Abstract: | © 2018 Sociedad Española de Cardiología Introduction and objectives: The PARIS score allows combined stratification of ischemic and hemorrhagic risk in patients with ischemic heart disease treated with coronary stenting and dual antiplatelet therapy (DAPT). Its usefulness in patients with acute coronary syndrome (ACS) treated with ticagrelor or prasugrel is unknown. We investigated this issue in an international registry. Methods: Retrospective multicenter study with voluntary participation of 11 centers in 6 European countries. We studied 4310 patients with ACS discharged with DAPT with ticagrelor or prasugrel. Ischemic events were defined as stent thrombosis or spontaneous myocardial infarction, and hemorrhagic events as BARC (Bleeding Academic Research Consortium) type 3 or 5 bleeding. Discrimination and calibration were calculated for both PARIS scores (PARIS ischemic and PARIS hemorrhagic ). The ischemic-hemorrhagic net benefit was obtained by the difference between the predicted probabilities of ischemic and bleeding events. Results: During a period of 17.2 ± 8.3 months, there were 80 ischemic events (1.9% per year) and 66 bleeding events (1.6% per year). PARIS ischemic and PARIS hemorrhagic scores were associated with a risk of ischemic events (sHR, 1.27; 95%CI, 1.16-1.39) and bleeding events (sHR, 1.14; 95%CI, 1.01-1.30), respectively. The discrimination for ischemic events was modest (C index = 0.64) and was suboptimal for hemorrhagic events (C index = 0.56), whereas calibration was acceptable for both. The ischemic-hemorrhagic net benefit was negative (more hemorrhagic events) in patients at high hemorrhagic risk, and was positive (more ischemic events) in patients at high ischemic risk. Conclusions: In patients with ACS treated with DAPT with ticagrelor or prasugrel, the PARIS model helps to properly evaluate the ischemic-hemorrhagic risk. Full English text available from: www.revespcardiol.org/en | URI: | https://open.uns.ac.rs/handle/123456789/495 | ISSN: | 3008932 | DOI: | 10.1016/j.recesp.2018.02.008 |
Appears in Collections: | MDF Publikacije/Publications |
Show full item record
SCOPUSTM
Citations
8
checked on May 10, 2024
Page view(s)
28
Last Week
2
2
Last month
0
0
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.